BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22330331)

  • 1. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
    Morris PG; Fazio M; Farooki A; Estilo C; Mallam D; Conlin A; Patil S; Fleisher M; Cremers S; Huryn J; Hudis CA; Fornier MN
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2768-75. PubMed ID: 22330331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
    Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
    Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
    Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
    Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
    J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
    Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
    J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
    Lee CY; Suzuki JB
    Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
    J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
    Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
    J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
    Izumi K; Mizokami A; Itai S; Shima T; Shigehara K; Miwa S; Maeda Y; Konaka H; Koh E; Namiki M
    BJU Int; 2012 Feb; 109(3):394-400. PubMed ID: 21599822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study.
    Demircan S; Isler SC
    Niger J Clin Pract; 2020 Feb; 23(2):154-158. PubMed ID: 32031088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
    Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
    Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
    Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
    Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.